Cent Eur J Public Health 2011, 19(3):128-130 | DOI: 10.21101/cejph.a3653
Prevalence of Human Leukocyte Antigen (HLA)-B*5701 in HIV-infected Subjects in Czech Republic
- 1 Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University in Prague, Czech Republic
- 2 University Hospital Bulovka, Prague, Czech Republic
- 3 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 4 Department of Infectious Diseases, University Hospital Brno, Czech Republic
- 5 Department of Infectious Diseases, Medical Faculty of Charles University and Faculty Hospital, Plzeň, Czech Republic
- 6 Department of Infectious Diseases, University Hospital Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 7 Department of Infectious Diseases, Faculty Hospital Ostrava, Ostrava, Czech Republic
- 8 Department of Infectious Diseases, Hospital České Budějovice, České Budějovice, Czech Republic
- 9 Department of Biostatistics, National Institute of Public Health, Prague, Czech Republic
- 10 Department of Infectious Diseases, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir, and its prevalence varies in different populations. The aim of the study was to investigate HLA-B*57:01 prevalence in the Czech HIV-infected population. HLA-B*57:01 prevalence in our cohort was 5.33%, which is similar to the situation in other Central European countries.
Klíčová slova: abacavir, hypersensitivity, HLA-B*57:01, prevalence, Czech Republic
Vloženo: 19. listopad 2010; Revidováno: 25. květen 2011; Přijato: 25. květen 2011; Zveřejněno: 1. září 2011 Zobrazit citaci
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
Jilich D, Vraná M, Snopková S, Sedláček D, Kapla J, Rozsypal H, et al.. Prevalence of Human Leukocyte Antigen (HLA)-B*5701 in HIV-infected Subjects in Czech Republic. Cent Eur J Public Health. 2011;19(3):128-130. doi: 10.21101/cejph.a3653. PubMed PMID: 22026283.
Reference
- Hetherington S, McGuirk S, Powell G, CutrellA, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001 Oct;23(10):1603-14.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002 Mar 2;359(9308):727-32.
Přejít k původnímu zdroji...
- Hetherington S, HughesAR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002 Mar 30;359(9312):1121-2.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008 Mar;42(3):387-96.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005 Jun 10;19(9):979-81.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568-79.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004 Jun;14(6):335-42.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008 Apr 1;46(7):1111-8.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Allele Frequencies in Worldwide Populations [Internet]. Liverpool: The Allele Frequency net; 2011 [cited 2010 Nov 19]. Available from: http://www.allelefrequencies.net.
- Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, et al. Incidence of abacavir hypersensitivity and its relationship with HLAB*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007 Sep;60(3):599-604.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Zahlavova L, Bendukidze N, Ivaskova E. HLA-A, -B, -Cw, -DPB1, -DQA1, -DQB1 and -DRB1 allele frequencies in a population from the Czech Republic. Hum Immunol. 2004;65(9-10):925-30.
Přejít k původnímu zdroji...
- Orkin C, Sadiq ST, Rice L, Jackson F; UK EPI team. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)B*5701 in HIV-1-infected UK subjects. HIV Med. 2010 Mar;11(3):18792.
Přejít k původnímu zdroji...
Přejít na PubMed...
- Tumanov A, Laga V, Kazennova O, et al. The prevalence of the HLAB*5701 allele in the European part of the Russian Federation.12th European AIDS Conference/EACS. HIV Med. 2009;10 (Suppl.2):84.
- Parczewski M, Leszczyszyn-Pynka M, WnukA, UrbañskaA, Fuksiñska K, Bander D, et al. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients. HIV Med. 2010 May;11(5):345-8.
Přejít k původnímu zdroji...
Přejít na PubMed...